Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity

With shrinking debt, investors signal strong support for the life-sciences company’s planned uplisting to a national exchange
A pressure gadget
Hundreds of labs utilize the company's pressure-based systems to extract proteins from cells

Pressure BioSciences Inc (OTCMKTS:PBIO) continued to strengthen its balance sheet Tuesday with the conversion of an additional US$7.24mln of debt into equity, bringing the total amount of debt that has converted into equity over the past four weeks to more than US$13.6mln.

If the company successfully persuades more debt holders to follow suit and swap their debt for equity, it would increase the life sciences company’s chance of uplisting to a national exchange, such as Nasdaq, later this year.

“We are continuing to discuss the company's progress with remaining debt holders, and anticipate that several more may follow the lead of the approximate 40-plus investors who converted their debt into equity over the past 30 days,” said Pressure BioSciences CFO Joseph L. Damasio. "We believe such further conversions could reduce the amount of loan debt on our balance sheet by an additional 10% to 15%," he added.

READ: Callitas Health, ChemioCare and Pressure BioSciences make a splash at Proactive Investors forum

As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground.  

“We are very pleased to have been able to clean up the balance sheet as much as we have over the past 30 days,” Pressure BioSciences CEO Richard Schumacher said in an emal to Proactive Investors. “Of course, there is more work to be done, which we are excited to be tackling.”

Schumacher noted that the company had successfully accessed debt for working capital. “This has allowed us to increase revenue, enlarge our customer base, enhance our instrument and consumables line, expand our sales and marketing reach, add much-needed manufacturing and development space, and strengthen other internal operational areas.”

He said that at a “strategic level,” debt capital had allowed the company to attain “initial progress and IP issuances” in its new Ultra Shear Technology platform, and to acquire all of BaroFold Corp.'s assets.

“We believe that both of these strategic programs will bring about substantial expansion in major new business segments,” said Schumacher.

The Harvard Medical School trained serial entrepreneur who has founded four companies is extremely enthusiastic about the first contract Pressure BioSciences has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” Schumacher had earlier told proactive investors. “It’s all coming together this year.”

WATCH: Pressure BioSciences CEO sees increased revenue on projects and services in 2018

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to over 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Focus on uplisting to a national exchange

Meanwhile, Jeffrey N. Peterson, chairman of the board, said the conversion of “a majority of our loan debt into equity” would help Pressure BioSciences in its quest to uplist to a national exchange.

"We believe Pressure BioSciences Inc’s recent accomplishments, when combined with the conversion of a majority of our loan debt into equity, will materially facilitate progress towards our stated objective of uplisting to a national exchange (NASDAQ, NYSE/Amex) later in 2018,” said Peterson.

“We believe a national exchange trading platform will provide improved access to capital and trading volumes, and that these should result in a more attractive and higher-value recognition level for the company, benefitting all shareholders," he added.

Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in the area of high pressure-based technologies, platforms, and services.

Hundreds of labs utilize the company's pressure-based systems to extract proteins from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

Pressure Biosciences' shares traded flat amid a broader market pullback.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
cells
July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use